Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders

References

• Rosamond W, Flegal K, Friday G et al. Heart disease and stroke statistics–2007 Update: a report from the American Heart Association Statistic Committee and Stroke Statistics Subcommittee. Circulation115, e69–e171 (2007).
   PubMed Web of Science ®Google Scholar
• Wong ND, Kashyap M. Cholesterol and lipids chapters. In: Preventive Cardiology (2nd Edition). Wong ND, Black HR, Gardin JM (Eds). McGraw–Hill, NY, USA (2004).
   Google Scholar
• Robins SJ, Collins D, Wittes JT et al.; VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA285(12), 1585–1591 (2001).
   PubMed Web of Science ®Google Scholar
• Expert Panel and Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Educational Program (NCEP) expert panel and detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation106, 3143–3421 (2002).
   PubMed Web of Science ®Google Scholar
• LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized-control trials. JAMA282, 2340–2346 (1999).
   PubMed Web of Science ®Google Scholar
• Myers C D, Kamanna VS, Kashyap ML. Niacin therapy in atherosclerosis. Curr. Opin. Lipidol.15, 659–665 (2004).
   PubMedGoogle Scholar
• Carlson LA. Nicotinic acid: the broad-spectrum lipid drugs. A 50th anniversary review. J. Intern. Med.258, 94–114 (2005).
   PubMed Web of Science ®Google Scholar
• Stein EA, Davison MH, Dujovne CA et al. Efficacy and tolerability of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: a prospective trial. J. Cardiovasc. Pharmacol. Ther.1, 107–116 (1996).
   PubMedGoogle Scholar
• Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N.Engl. J. Med.345, 1582–1592 (2001).
   Google Scholar
• Taylor AJ, Sullenberger LE, Lee HJ et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2. A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statin. Circulation110, 3512–3517 (2004).
   PubMed Web of Science ®Google Scholar
• Altschultz R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch. Biochem. Biophys.54, 558–559 (1995).
   Google Scholar
• Tavintharan S, Kashyap ML. The benefits of niacin in atherosclerosis. Curr. Atheroscler. Rep.3, 74–82 (2001).
   PubMedGoogle Scholar
• The Coronary Drug Project Research Group: clofibrate and niacin in coronary heart disease. JAMA231, 360–381 (1975).
   PubMed Web of Science ®Google Scholar
• Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefits with niacin. J. Am. Coll. Cardiol.8, 1245–1255 (1986).
   PubMed Web of Science ®Google Scholar
• McKenney J. New prospective on the use of niacin in the treatment of lipid disorders. Arch. Intern. Med.164(7), 697–705 (2004).
   PubMed Web of Science ®Google Scholar
• Cefali EA, Simmons PD, Stanek, EJ et al. Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation. Int. J. Clin. Pharmacol. Ther.44, 633–640 (2006).
   PubMed Web of Science ®Google Scholar
• Cefali EA, Simmons PD, Stanek EJ et al. Aspirin reduces cutaneous flushing after administration of an optimized extended-released niacin formulation. Int. J. Clin. Pharmacol. Ther.45, 78–88 (2007).
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet344, 1383–1389 (1994).
   PubMed Web of Science ®Google Scholar
• Insull W, Mc Govern ME, Schrott H et al. Efficacy of extended-release niacin with lovastatin for hypercholesterolemia. Arch. Intern. Med.164, 1121–1127 (2004).
   PubMed Web of Science ®Google Scholar
• Karas RH, Kashyap ML, Knopp R et al. Long-term safety and efficacy of a combination of extended-release niacin and simvastatin in patients with dyslipidemia: The OCEANS Study. Am. J. Cardiovasc. Drugs8(2), 69–81 (2008).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Davidson MH, McKenney J et al. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am. J. Cardiol.101, 1428–1436 (2008).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Davidson MH, McKenney J et al. Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80mg monotherapy: the SEACOAST II (high dose) study. J. Clin. Lipidol.2, 79–90 (2008).
   PubMed Web of Science ®Google Scholar
• The Merck Index. An Encyclopedia of Chemical, Drug and Biologicals. Niacin. Budavari S, O’Neil MJ, Smith A, Hecklelman PE (Eds). Merck &Co., Inc., NJ, USA (1989).
   Google Scholar
• The Merck Index. An Encyclopedia Of Chemical, Drug And Biologicals. Simvastatin. Budavari S, O’Neil MJ, Smith A, Hecklelman PE (Eds). Merck &Co. Inc., NJ , USA (1989).
   Google Scholar
• Knopp RH, Alagona P, Davidson M et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the managment of hyperlipidemia. Metabolism47(9), 1097–1104 (1998).
   PubMed Web of Science ®Google Scholar
• Guyton JR, Goldberg AC, Kreisberg RA et al. Effectiveness of once-daily dosing of extended-release niacin alone or in combination for hypercholesterolemia. Am. J. Cardiol.82(6), 737–743 (1998).
   PubMed Web of Science ®Google Scholar
• Capuzzi DM, Guyton JR, Morgan JM et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am. J. Cardiol.82, 74U–81U (1998).
   PubMed Web of Science ®Google Scholar
• Sakai T, Kanmanna VS, Kashyap ML. Niacin but not gemfibrozil increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL-cholesterol. Arterioscler. Throm. Vasc. Biol.21, 1783–1789 (2001).
   PubMed Web of Science ®Google Scholar
• Jin FY, Kamanna VS, Kashyap ML. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 Cells. Implication for reverse cholesterol transport. Artheroscler. Thromb. Vasc. Biol.17, 2020–2028 (1997).
   PubMed Web of Science ®Google Scholar
• Zhang L, Kamanna VS, Zhang MC, Kashyap ML. Niacin inhibits surface expression of ATP synthase β chain in HepG2 cells: implications for raising HDL. J. Lipid Res.49, 1195–1201 (2008).
   PubMed Web of Science ®Google Scholar
• Carlson LA. Studies on the effects of nicotinic acid on catecholamide stimulated lipolysis in adipose tissue in vitro. Acta Med. Scand.173, 719–722 (1963).
   PubMed Web of Science ®Google Scholar
• Jin FY, Kamanna VS, Kashyap ML. Niacin accelerates intracellular apo B degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (Hep G2) cells. Artherioscler. Thromb. Vasc. Biol.19, 1051–1059 (1999).
   PubMed Web of Science ®Google Scholar
• Ganji SH, Tavintharan S, Zhu D et al. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J. Lipid Res.45, 1835–1945 (2004).
   PubMed Web of Science ®Google Scholar
• Kamanna VS, Kashyap ML. Mechanism of action of niacin on lipoprotein metabolism. Curr. Atheroscl. Rep.2, 36–46 (2002).
   Google Scholar
• Kashyap ML. Mechanistic studies of high density lipoprotein. Am. J. Cardiol.82, 42U–46U (1998).
   PubMed Web of Science ®Google Scholar
• Brinton EA, Jiang P, Thakkar R, Padley RJ. Extended-release niacin combined with simvastatin increases an antiatherogenic HDL subfraction.Arterioscler. Thromb. Vasc. Bio.28 (Abstract e93) (2008).
   Google Scholar
• Kamanna VS, Kashyap ML. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents? Am. J. Cardiol.100(11 A), S53–S61 (2007).
   Google Scholar
• Mauro VF, MacDonald JL. Simvastatin: a review of its pharmacology and clinical use. Ann. Pharmacother.25, 257–264. (1991).
   Google Scholar
• Plosker GL, McTavish D. Simvastatin: a reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolemia. Drugs50, 334–363 (1995).
   PubMed Web of Science ®Google Scholar
• Meredith KG, Horne BD, Pearson RR et al. Comparison of effects of high (80 mg) versus low (20 mg) dose of simvastatin on C-reactive protein and lipoproteins in patients with angiographic evidence of coronary arterial narrowing. Am. J. Cardiol.99(2), 149–153 (2007).
   PubMedGoogle Scholar
• Bays HE, Stein EA, Shah AK et al. Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients. Am. J. Cardiol.90(9), 942–946 (2002).
   PubMedGoogle Scholar
• Albert MA, Danielson E, Rifai N et al. Effect of statin therapy on C-reactive protein levels: The Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA286, 64–670 (2001).
   PubMed Web of Science ®Google Scholar
• Piepho RW. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am. J. Cardiol.86, 35L–40L (2000).
   Web of Science ®Google Scholar
• Benyo Z, Gille A, Kero J et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J. Clin. Invest.115, 3634–3640 (2005).
   PubMed Web of Science ®Google Scholar
• Benyo Z, Gille A, Benett C et al. Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells. Mol. Pharm.70, 1844–1849 (2006).
   PubMed Web of Science ®Google Scholar
• Stern RH, Freeman D, Spence JD. Differences in metabolism of time-release and unmodified nicotinic acid: explanation of the differences in hypolipidemic action? Metabolism41, 879–881 (1992).
   PubMedGoogle Scholar
• SIMCOR®, prescribing information. Abbott Laboratories, IL, USA (2008).
   Google Scholar
• Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol level: results of AFCAPS/TexCAPS. JAMA279, 1615–1622 (1998).
   PubMed Web of Science ®Google Scholar
• Canner PL, Berge KG, Wenger NK et al. Fifteen-years mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol.8, 1245–1255 (1986).
   PubMed Web of Science ®Google Scholar
• Strandberg TE, Pyorala K, Cook TJ et al. Mortality and incidence of cancer during 10 years follow up of the Scandinavian Simvastatin Survival Study (4S). Lancet364, 771–777 (2004).
   PubMed Web of Science ®Google Scholar
• Heart Protection Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20,536 high risk individuals: a randomized placebo controlled trial. Lancet360, 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Blankenhorn DH, Nessim SA, Johnson RL et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass graft. JAMA257, 3233–3240 (1987).
   PubMed Web of Science ®Google Scholar
• Brown BG, Albers JJ, Fisher LD. Regression of coronary disease as a result of intensive lipid-lowering therapy in men with high level of apolipoprotein B. N. Engl. J. Med.323, 1289–1298 (1990).
   PubMed Web of Science ®Google Scholar
• Zhao XQ, Morse JS, Dowdy AA et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (the HDL Atherosclerosis Treatment Study). Am. J. Cardiol.93, 307–312 (2004).
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Lee HJ, Sullenberger LE et al. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr. Med. Res. Opin.22(11), 2243–2250 (2006).
   PubMed Web of Science ®Google Scholar
• Robinson JG, Davidson MH. Combination therapy with ezetimibe and simvastatin to achieve LDL reduction. Expert Rev. Cardiovasc. Ther.4(4), 461–476 (2006).
   PubMedGoogle Scholar
• Grundy SM, Vega GL, Yuan Z et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am. J. Cardiol.95, 462–468 (2005).
   PubMed Web of Science ®Google Scholar
• Davidson MH, Stein EA, Bays HE et al. Efficacy and tolerability of adding prescription omega-3 fatty acid 4g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double blind, placebo-controlled study. Clin. Ther.29, 1354–1367 (2007).
   PubMed Web of Science ®Google Scholar